Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112

  • Wildcard search for 'clinic*' used only the first 600 variations. Lengthen the root word to search for all endings.
1.

Long non-coding RNA SNHG12promotes the proliferation and migration of glioma cells by binding to HuR.

Lei W, Wang ZL, Feng HJ, Lin XD, Li CZ, Fan D.

Int J Oncol. 2018 Jul 11. doi: 10.3892/ijo.2018.4478. [Epub ahead of print]

PMID:
30015836
2.

Reduced RNA-binding protein HuD in pancreatic neuroendocrine tumors lowers p27Kip1 levels linked to poor prognosis.

Kim C, Jeong DE, Heo S, Ji E, Rho JG, Jung M, Ahn S, Kim YJ, Kim YS, Nam SW, Kulkarni RN, Lee KB, Lee EK, Kim W.

J Pathol. 2018 Jul 17. doi: 10.1002/path.5135. [Epub ahead of print]

PMID:
30014466
3.

Clinical Significance and Biological Role of HuR in Head and Neck Carcinomas.

Levidou G, Kotta-Loizou I, Tasoulas J, Papadopoulos T, Theocharis S.

Dis Markers. 2018 Jan 28;2018:4020937. doi: 10.1155/2018/4020937. eCollection 2018. Review.

4.

High cytoplasmic HuR expression is associated with advanced pT stage, high grade and increased microvessel density in urothelial bladder carcinoma.

Fus ŁP, Pihowicz P, Koperski Ł, Marczewska JM, Górnicka B.

Ann Diagn Pathol. 2018 Apr;33:40-44. doi: 10.1016/j.anndiagpath.2017.12.002. Epub 2017 Dec 13.

PMID:
29566946
5.

HuR, TTP, and miR-133b expression in NSCLC and their association with prognosis.

Qian L, Ji AH, Zhang WJ, Zhao N.

Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):430-442. doi: 10.26355/eurrev_201801_14192.

6.

Up-regulation of miR-324-5p inhibits proliferation and invasion of colorectal cancer cells by targeting ELAVL1.

Gu C, Zhang M, Sun W, Dong C.

Oncol Res. 2018 Jan 31. doi: 10.3727/096504018X15166183598572. [Epub ahead of print]

PMID:
29386086
7.

Over-expression of oncigenic pesudogene DUXAP10 promotes cell proliferation and invasion by regulating LATS1 and β-catenin in gastric cancer.

Xu Y, Yu X, Wei C, Nie F, Huang M, Sun M.

J Exp Clin Cancer Res. 2018 Jan 27;37(1):13. doi: 10.1186/s13046-018-0684-8.

8.

Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis.

Lin C, Zhang S, Wang Y, Wang Y, Nice E, Guo C, Zhang E, Yu L, Li M, Liu C, Hu L, Hao J, Qi W, Xu H.

Clin Cancer Res. 2018 Jan 15;24(2):486-498. doi: 10.1158/1078-0432.CCR-17-1851. Epub 2017 Nov 3.

PMID:
29101304
9.

Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.

Giaginis C, Sampani A, Kotta-Loizou I, Giannopoulou I, Danas E, Politi E, Tsourouflis G, Kouraklis G, Patsouris E, Keramopoulos A, Nakopoulou L, Theocharis S.

Pathol Oncol Res. 2018 Jul;24(3):631-640. doi: 10.1007/s12253-017-0288-1. Epub 2017 Aug 14.

10.

Hu antigen R (HuR) multimerization contributes to glioma disease progression.

Filippova N, Yang X, Ananthan S, Sorochinsky A, Hackney JR, Gentry Z, Bae S, King P, Nabors LB.

J Biol Chem. 2017 Oct 13;292(41):16999-17010. doi: 10.1074/jbc.M117.797878. Epub 2017 Aug 8.

PMID:
28790173
11.

Silencing of the RNA-binding protein HuR attenuates hyperalgesia and motor disability in experimental autoimmune encephalomyelitis.

Sanna MD, Quattrone A, Galeotti N.

Neuropharmacology. 2017 Sep 1;123:116-125. doi: 10.1016/j.neuropharm.2017.06.005. Epub 2017 Jun 12.

PMID:
28599923
12.

RNA-binding protein HuR promotes bladder cancer progression by competitively binding to the long noncoding HOTAIR with miR-1.

Yu D, Zhang C, Gui J.

Onco Targets Ther. 2017 May 17;10:2609-2619. doi: 10.2147/OTT.S132728. eCollection 2017.

13.

HuR promotes breast cancer cell proliferation and survival via binding to CDK3 mRNA.

Zhang Z, Huang A, Zhang A, Zhou C.

Biomed Pharmacother. 2017 Jul;91:788-795. doi: 10.1016/j.biopha.2017.04.063. Epub 2017 May 10.

PMID:
28501005
14.

A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy.

Wu X, Wang SH, Sun J, Krainer AR, Hua Y, Prior TW.

Hum Mol Genet. 2017 Jul 15;26(14):2768-2780. doi: 10.1093/hmg/ddx166.

15.

Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities.

Su SC, Lin CW, Liu YF, Fan WL, Chen MK, Yu CP, Yang WE, Su CW, Chuang CY, Li WH, Chung WH, Yang SF.

Theranostics. 2017 Feb 26;7(5):1088-1099. doi: 10.7150/thno.18551. eCollection 2017.

16.

Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H.

Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12.

17.

Novel LINS1 missense mutation in a family with non-syndromic intellectual disability.

Sheth J, Ranjan G, Shah K, Bhavsar R, Sheth F.

Am J Med Genet A. 2017 Apr;173(4):1041-1046. doi: 10.1002/ajmg.a.38089. Epub 2017 Feb 9.

PMID:
28181389
18.

Study on the Single Dose Toxicity of ShinEumHur Pharmacopuncture Injected into the Muscles of Rats.

Jeong H, Cha E, Lee J, Lee S, Park M, Kim D, Song B, Lee J, Kim S.

J Pharmacopuncture. 2016 Dec;19(4):350-358. doi: 10.3831/KPI.2016.19.037.

19.

HuR and podoplanin expression is associated with a high risk of malignant transformation in patients with oral preneoplastic lesions.

Habiba U, Kitamura T, Yanagawa-Matsuda A, Higashino F, Hida K, Totsuka Y, Shindoh M.

Oncol Lett. 2016 Nov;12(5):3199-3207. Epub 2016 Aug 29.

20.

Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.

Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR.

Ann Surg. 2018 Feb;267(2):364-369. doi: 10.1097/SLA.0000000000002088.

PMID:
27893535

Supplemental Content

Loading ...
Support Center